KB801

Phase 2Biologic

KKrystal Biotech, Inc.

KB801 is one of 15 biologic programs targeting Keratitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratitisRecruiting

KeratitisPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Keratitis

#DrugCompanyPhaseTrials

Neoral

Avelox

Rayos

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—5

Decadron

AAspen Global Incorporated

Levaquin

OXERVATE

DDompé Farmaceutici S.p.A

Approved

1 8

Cytovene

EExela Pharma Sciences, LLC.

Preclinical

2 9

Zovirax

BBp Consulting, Inc

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Keratitis

NCT06999733

Clinical

Trials by Indication[1]

Keratitis1 trial

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

Recruiting·KKrystal Biotech, Inc.·Phase 1/2·NCT06999733·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KB801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KB801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KB801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Krystal Biotech, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: KKrystal Biotech, Inc.

KB801

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Keratitis1 trial

References

Drug Info

Quick Facts

Related News